1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shamrock Industrial Co. Ltd.

Shamrock Industrial Co. Ltd.

BBSE:SHAMROIN
27.25
INR
0.00
(0.00%)
-1.97EPS
127.89MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.03
-0.07
-3.76
-0.04
-0.12
-0.53
-0.4
-0.58
-0.38
-0.24
-0.07
-0.23
-2
-1.97
Free Cash Flow per Basic Share
- -
- -
-3.53
- -
- -
-15.85
-1.04
-0.58
-0.63
-0.06
-0.07
-0.24
-1.92
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
1.51
5.62
5.51
5.39
4.86
4.46
3.88
3.5
3.26
3.19
2.96
0.95
- -
Tangible Book Value per Share
- -
1.51
5.62
5.51
5.39
4.86
4.46
3.88
3.5
3.26
3.19
2.96
0.95
- -
Basic Weighted Avg Shares
6
5
5
13
5
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-20
-1
-1
-3
-2
-3
-2
-1
- -
-1
-11
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
1
-45
-46
-47
25
23
20
18
17
16
15
5
- -
LT Debt
- -
88
45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
8
30
30
29
26
24
21
19
18
17
16
5
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-105.51
-1.85
-2.17
-10.35
-8.68
-13.86
-10.35
-7
-2.32
-7.56
-102.52
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
7
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
105
116
128

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
17
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
11
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
7
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-12.91%
-18.81%
-67.85%
Free Cash Flow
-50,443.33%
175.89%
702.31%
Net Income, GAAP
111.84%
166.47%
762.38%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.1
-0.04
-0.04
-0.05
-0.23
2026
-0.21
-0.58
-1.01
-0.19
-2
2027
-0.19
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rattan Kapoor
Full Time Employees
1
Sector
Health technology
Industry
Pharmaceuticals: major
Address
83 – E, Hansraj Pragji Building Mumbai MA India 400018
IPO Date
Sep 4, 1995
Website
shamrockindustrial.wordpress.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shamrock Industrial Company Limited (BSE: SHAMROIN.BO) manufactures and deals in pharmaceutical products, including active pharmaceutical ingredients (APIs), advanced intermediates, intermediates, and fine chemicals for therapeutic applications such as anti-coagulants, anti-platelets, radio-protective agents, platelet regulators, anti-depressants, anti-neoplastics, immunosuppressants, antihistamines, sympathomimetics, anti-hypertensives, diuretics, anti-diabetics, calcium regulating agents, local anesthetics, and anti-bacterials; manufactured APIs include acenocoumarol, amifostine, ciclopirox, cilazapril, losartan potassium, metaxalone, metoprolol succinate, and pregabalin, while contract manufactured APIs encompass abacavir, acarbose, oxaliplatin, oxaprozin, finasteride, frusemide, and colchicine. The company partners exclusively with manufacturing facilities in Ankleshwar, Vadodara, Chennai, and Ambernath, India, to produce high-quality APIs and intermediates, with 100% of sales comprising exports to over 35 countries worldwide, primarily serving the pharmaceutical and healthcare industries. Founded in 1991 and headquartered in Mumbai, India, Shamrock Industrial operates as a BSE-listed public limited company with authorized capital of Rs. 10 crore and paid-up capital of Rs. 5.43 crore. In recent developments, the company underwent significant management changes on October 16, 2025, with the board appointing Rattan Kapoor as Managing Director/CEO for a five-year term and Aryan Chand as Chief Business Officer, alongside the resignation of four directors. Earlier in October 2025, disclosures were filed under SEBI (SAST) Regulations for substantial acquisition of shares, indicating potential shifts in ownership or control. These operational and leadership transitions mark key strategic realignments within the last year, amid ongoing low profitability and zero sales reported in recent financials.